HC Wainwright Reiterates Buy Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They presently have a $9.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 182.13% from the company’s current price.

GANX has been the subject of a number of other research reports. Oppenheimer reiterated an “outperform” rating and set a $9.00 target price on shares of Gain Therapeutics in a research report on Tuesday. Chardan Capital restated a “buy” rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, March 27th.

Gain Therapeutics Trading Down 5.9 %

Shares of GANX stock opened at $3.19 on Thursday. The stock has a market cap of $51.74 million, a price-to-earnings ratio of -1.87 and a beta of 0.43. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.59 and a current ratio of 3.59. The firm has a fifty day moving average of $4.04 and a 200-day moving average of $3.44. Gain Therapeutics has a 52-week low of $2.00 and a 52-week high of $5.65.

Gain Therapeutics (NASDAQ:GANX) last announced its earnings results on Tuesday, March 26th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03. On average, equities research analysts forecast that Gain Therapeutics will post -1.17 earnings per share for the current fiscal year.

Insider Activity

In other Gain Therapeutics news, Director Jeffrey Scott Riley bought 30,000 shares of Gain Therapeutics stock in a transaction dated Thursday, March 28th. The shares were bought at an average price of $3.86 per share, with a total value of $115,800.00. Following the purchase, the director now owns 30,000 shares of the company’s stock, valued at $115,800. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 11.00% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.